Self-medication with herbal medicine and breast cancer survival: a prospective monocentric study.
Alternative medicine
Breast cancer
Complementary medicines
Interaction
Neoplasm
Phytotherapy
Survival
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
29
01
2021
accepted:
16
03
2021
pubmed:
23
3
2021
medline:
25
2
2023
entrez:
22
3
2021
Statut:
ppublish
Résumé
The use of complementary and alternative medicine (CAM) is common among breast cancer patients, but less is known about whether CAM influences breast cancer survival. The primary aim of this study was to determine the impact of self-use of herbs on the overall survival. This was a prospective study including 110 patients with breast cancer. All patients were questioned about the concept of taking herbs. We analyzed the demographic data and the overall survival. The average age was 51 years (30-80 years old). 37 had metastatic disease (33.6%). 48 patients had taken plants (43.6%). 19 patients consumed Graviola (39.6%) and 29 Alenda (60.4%). Overall survival at 3 years and at 5 years were, respectively, 96.2% and 82.4% in the absence of plant consumption versus 78.5% and 78.5% in case of plant consumption (p = 0.015). This study concluded that self-medication with Graviola or Alenda may be associated with an increase of death risk in patients with breast cancer. Further studies are needed to confirm these results.
Identifiants
pubmed: 33748880
doi: 10.1007/s00432-021-03600-y
pii: 10.1007/s00432-021-03600-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3401-3407Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Cassileth BR, Lucarelli CD (2003) Herb–drug interactions in oncology. BC Decker Inc, Hamilton
Caveny S, Charlet D, Freitqg H, Maier-Stolete M, Starratt A (2001) New observations on the secondarychemistry of world Ephedra (Ephedraceae). Am J Botan 88:1199–1208
doi: 10.2307/3558330
Chabosseau S, Derbré S (2016) Cancer du sein: recommandations sur l’usage de la phytothérapie. Actual Pharm 55(552):45–49
Chen W, Tsai T, Yang C, Kuo T (2010) Effects of ephedra on autonomicnervous modulation in healthy young adults. J Ethnopharmacol 130:563–568
doi: 10.1016/j.jep.2010.05.056
Complementary, alternative, or integrative health: what’s in a name? | NCCIH (2016) National center for complementary and integrative health. https://nccih.nih.gov/health/integrative-health . Accessed 30 Nov 2017
Danciu C, Muntean D, Alexa E, Farcas C, Oprean C, Zupko I et al (2018) Phytochemical characterization and evaluation of the antimicrobial, antiproliferative and pro-apoptotic potential of ephedra alata decne. Hydroalcoholic extractagainst the MCF-7 breast cancer cell line. Molecules 1:20–24
DiGianni LM, Garber J, Winer EP (2002) Complementary and alternative medicine use among women with breast cancer. J Clin Oncol 20:34S-48S
pubmed: 12235222
Drug information—express scripts ® (2018) https://www.expressscripts . com/medco/consumer/ehealth/druginfo/dlmain. jsp?WC=N. Accessed 5 Jan 2018
Ernst E, Cassileth BR (1998) The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 83:777–782
doi: 10.1002/(SICI)1097-0142(19980815)83:4<777::AID-CNCR22>3.0.CO;2-O
Firkins R, Eisfeld H, Keinki C, Buentzel J, Hochhaus A, Schmidt T et al (2018) The use of complementary and alternative medicine by patients in routine care and the risk of interactions. J Cancer Res Clin Oncol 144(3):551–557
doi: 10.1007/s00432-018-2587-7
Frenkel M, Ben-Arye E, Cohen L (2010) Communication in cancer care: discussing complementary and alternative medicine. Integr Cancer Ther 9:177–185
doi: 10.1177/1534735410363706
Huebner J, Muenstedt K, Prott FJ, Stoll C, Micke O, Buentzel J et al (2014a) Online survey of patients with breast cancer on complementary and alternative medicine. Breast Care (Basel Switzerland) 9(1):60–63
doi: 10.1159/000360381
Huebner J, Micke O, Muecke R, Buentzel J, Prott FJ, Kleeberg U et al (2014b) User rate of complementary and alternative medicine (CAM) of patients visiting a counseling facility for CAM of a German comprehensive cancer center. Anticancer Res 34(2):943–948
pubmed: 24511037
Integrative medicine: search about herbs | Memorial Sloan Kettering Cancer Center (2018) https://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs/search . Accessed 5 Jan 2018
John G, Hershman D, Falci L et al (2016) Complementary and alternative medicine use among US cancer survivors. J Cancer Surviv 10:850–864
doi: 10.1007/s11764-016-0530-y
Johnson S, Park H, Gross C, Yu J (2018) Complementary medicine, refusal of conventional cancer therapy, and survival among patients with curable cancers. JAMA Oncol 10:1375–1381
doi: 10.1001/jamaoncol.2018.2487
Jun HJ, Park SJ, Kang HJ, Lee GY, Lee N, Park JH et al (2020) The survival benefit of combination therapy with mild temperature hyperthermia and an herbal prescription of Gun-Chil-Jung in 54 cancer patients treated with chemotherapy or radiation therapy: a retrospective study. Integr Cancer Ther 19:1534735420926583
doi: 10.1177/1534735420926583
Ma H, Carpenter CL, Sullivan-Halley J, Bernstein L (2011) The roles of herbal remedies in survival and quality of life among long-term breast cancer survivors—results of a prospective study. BMC Cancer 6(11):222
doi: 10.1186/1471-2407-11-222
Matthews AK, Sellergren SA, Huo D, List M, Fleming G (2007) Complementary and alternative medicine use among breast cancer survivors. J Altern Complement Med 13(5):555–562
doi: 10.1089/acm.2007.03-9040
Neuhouser ML, Smith AW, George SM et al (2016) Use of complementary and alternative medicine and breast cancer survival in the health, eating, activity, and lifestyle study. Breast Cancer Res Treat 160:539–546
doi: 10.1007/s10549-016-4010-x
Pedersen CG, Christensen S, Jensen AB, Zachariae R (2009) Prevalence, socio-demographic and clinical predictors of post-diagnostic utilisation of different types of complementary and alternative medicine (CAM) in a nationwide cohort of Danish women treated for primary breast cancer. Eur J Cancer 45(18):3172–3181
doi: 10.1016/j.ejca.2009.09.005
Peters C, O’neill J, Young J (2005) Is there an association between ephedra and heartfailure? a case series. J Cardiac Fail 11:9–11
doi: 10.1016/j.cardfail.2004.04.003
Risberg T, Lund E, Wist E, Kaasa S, Wilsgaard T (1998) Cancer patients use of nonproven therapy: a 5 year follow-up study. J Clin Oncol 16:6–12
doi: 10.1200/JCO.1998.16.1.6
Risberg T, Vickers A, Bremnes RM, Wist EA, Kaasa S, Cassileth BR (2003) Does use of alternative medicine predict survival from cancer? Eur J Cancer 39:372–377
doi: 10.1016/S0959-8049(02)00701-3
Werneke U, Ladenheim D, McCarthy T (2004) Complementary alternative medicine for cancer: a review of effectiveness and safety. Cancer Ther 2:475–500
Woo M, Chung S, Kim D (1999) Cis-annonacin and (2,4)-cis-and trans-isoannonacins: cytotoxic monotetrahydrofuran annonaceous acetogenins from the seeds of Annona cherimolia. Arch Pharm Res 5:524–528
doi: 10.1007/BF02979164